Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Tigecycline-related pancreatitis: a review of spontaneous adverse event reports.

Okon E, Engell C, van Manen R, Brown J.

Pharmacotherapy. 2013 Jan;33(1):63-8. doi: 10.1002/phar.1159. Review.

PMID:
23307547
2.

Potential for linezolid-related blindness: a review of spontaneous adverse event reports.

Brown J, Aitken SL, van Manen RP.

Pharmacotherapy. 2011 Jun;31(6):585-90. doi: 10.1592/phco.31.6.585.

PMID:
21923442
3.

How safe are recently FDA-approved antimicrobials? A review of the FDA adverse event reporting system database.

Khadem TM, van Manen RP, Brown J.

Pharmacotherapy. 2014 Dec;34(12):1324-9. doi: 10.1002/phar.1519. Epub 2014 Nov 25.

PMID:
25421400
5.

Tigecycline-induced acute pancreatitis: case report and literature review.

Hung WY, Kogelman L, Volpe G, Iafrati M, Davidson L.

Int J Antimicrob Agents. 2009 Nov;34(5):486-9. doi: 10.1016/j.ijantimicag.2009.05.004. Epub 2009 Jun 18. Review.

PMID:
19540093
6.

The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database.

Raschi E, Piccinni C, Poluzzi E, Marchesini G, De Ponti F.

Acta Diabetol. 2013 Aug;50(4):569-77. doi: 10.1007/s00592-011-0340-7. Epub 2011 Oct 19.

PMID:
22008948
7.

Pancreatitis in tigecycline Phase 3 and 4 clinical studies.

McGovern PC, Wible M, Korth-Bradley JM, Quintana A.

J Antimicrob Chemother. 2014 Mar;69(3):773-8. doi: 10.1093/jac/dkt427. Epub 2013 Nov 11.

9.

Acute pancreatitis related to tigecycline: case report and review of the literature.

Gilson M, Moachon L, Jeanne L, Dumaine V, Eyrolle L, Morand P, Ben m'Rad M, Salmon D.

Scand J Infect Dis. 2008;40(8):681-3. doi: 10.1080/00365540801938949.

PMID:
18979610
10.

Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS).

Poluzzi E, Raschi E, Moretti U, De Ponti F.

Pharmacoepidemiol Drug Saf. 2009 Jun;18(6):512-8. doi: 10.1002/pds.1746.

PMID:
19358226
11.

Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).

DuMouchel W, Fram D, Yang X, Mahmoud RA, Grogg AL, Engelhart L, Ramaswamy K.

Ann Clin Psychiatry. 2008 Jan-Mar;20(1):21-31. doi: 10.1080/10401230701844612.

PMID:
18297583
12.

Duloxetine and pregnancy outcomes: safety surveillance findings.

Hoog SL, Cheng Y, Elpers J, Dowsett SA.

Int J Med Sci. 2013;10(4):413-9. doi: 10.7150/ijms.5213. Epub 2013 Feb 28.

13.

Drug-versus-drug adverse event rate comparisons: a pilot study based on data from the US FDA Adverse Event Reporting System.

Hochberg AM, Pearson RK, O'Hara DJ, Reisinger SJ.

Drug Saf. 2009;32(2):137-46. doi: 10.2165/00002018-200932020-00006.

PMID:
19236120
14.

Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.

Roberto G, Piccinni C, D'Alessandro R, Poluzzi E.

Cephalalgia. 2014 Jan;34(1):5-13. doi: 10.1177/0333102413499649. Epub 2013 Aug 6.

PMID:
23921799
16.

Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports.

Koller EA, Cross JT, Doraiswamy PM, Malozowski SN.

Pharmacotherapy. 2003 Sep;23(9):1123-30. Review.

PMID:
14524644
17.

Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution.

Chemaly RF, Hanmod SS, Jiang Y, Rathod DB, Mulanovich V, Adachi JA, Rolston KV, Raad II, Hachem RY.

Medicine (Baltimore). 2009 Jul;88(4):211-20. doi: 10.1097/MD.0b013e3181af01fc.

18.

Cardiovascular thromboembolic events associated with febuxostat: investigation of cases from the FDA adverse event reporting system database.

Gandhi PK, Gentry WM, Bottorff MB.

Semin Arthritis Rheum. 2013 Jun;42(6):562-6. doi: 10.1016/j.semarthrit.2012.11.002. Epub 2013 Jan 24.

PMID:
23352248
19.

T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.

Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED.

Am J Gastroenterol. 2013 Jan;108(1):99-105. doi: 10.1038/ajg.2012.334. Epub 2012 Oct 2.

PMID:
23032984
20.

Topical bovine thrombin: a 21-year review of topical bovine thrombin spontaneous case safety reports submitted to FDA's Adverse Event Reporting System.

Clark JA, Humphries JE, Crean S, Reynolds MW.

Pharmacoepidemiol Drug Saf. 2010 Feb;19(2):107-14. doi: 10.1002/pds.1874. Review.

PMID:
20014051

Supplemental Content

Support Center